A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. (Q54622155)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

phase II clinical trial

0 references

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Michael J Zelefsky

13

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Suzanne L Wolden

12

object named as

Suzanne Wolden

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

9

object named as

Dennis Kraus

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Bhuvanesh Singh

11

object named as

Bhuvanesh Singh

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

10

object named as

Ashok Shaha

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Andrew J Zahalsky

3

object named as

Andrew J Zahalsky

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

5

object named as

Eric Lis

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

author name string

David G Pfister

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

John McCaffrey

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Gary K Schwartz

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

William Gerald

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Andrew Huvos

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Ilana Palgi

14

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

publication date

1 February 2002

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

20

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

123-127

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of protein kinase C in antitumor treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12003188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1014449309165

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/12003188

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54622155&oldid=2212539409"